United States: Guidance On Patent Subject Matter Eligibility For Natural Phenomena And/Or Natural Products In The US: A Move In The Right Direction?

Last Updated: September 16 2015
Article by Tim Andrews

In decisions starting with Bilski (Bilski v. Kappos, 561 U.S. 593 (2010)), followed by Myriad (Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013)) and Mayo (Mayo v. Prometheus, 132 S. Ct. 1289 (2012)), and finally by Alice (Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 134 S. Ct. 2347 (2014)), the U.S. Supreme Court transformed the issue of patent eligibility, with far-reaching implications for the pharmaceutical and biotech industries and their ability to obtain fair protection for the fruits of their research. Here, we consider the developments of the eligibility guidelines, how they are applied (including a number of illustrative examples) and practical implications for the pharmaceutical and biotechnology industries, including potential approaches to patent claim drafting.

Initially, in response to Myriad and Mayo, the US Patent and Trademark Office (USPTO) released a memorandum entitled "Procedure For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products". This March 2014 Guidance applied to "claims (i.e., machine, composition, manufacture and process claims) reciting or involving laws of nature/natural principles, natural phenomena, and/or natural products".

The issuance of the March 2014 Guidance caused considerable and understandable concern in the biotechnology and pharmaceutical industries over exactly what might now be patent eligible. Few had imagined after the Myriad and Mayo decisions issued that the USPTO would seek to take the reasoning of those decisions (which, it had appeared, set a narrow exclusion to patentability to naturally occurring gene sequences) and extrapolate it to an extreme that most observers believe was never intended by the Courts. Section 101 eligibility in the US was always intended to be a coarse sieve, not a fine filter. The first months immediately after the issuance of the March 2014 Guidance saw a sharp rise in eligibility objections.

The USPTO embarked on an exercise in which it held meets with interested stakeholders, including representatives from the pharmaceutical and biotechnology industries. In the light of the feedback that it received, on 16 December 2014 the USPTO published its 2014 Interim Guidance on Patent Subject Matter Eligibility. This came into force with immediate effect and replaced the highly controversial earlier Guidance. It also supplemented the Guidance issued following the Alice Corp decision concerning abstract ideas issued earlier in 2014. The new Guidance requires the examiner to evaluate the claim as a whole. Examples are given of how the new approach should be applied, using the facts from previously decided cases including Myriad, Mayo and Alice. In the following, we discuss this new guidance and consider the practical implications for the pharmaceutical and biotechnology industries for the drafting, filing and prosecution of patent applications in the US directed to natural products.

It is firstly important to understand is that the December 2014 Guidance is for USPTO examiners to enable them to interpret the key Myriad, Mayo and Alice decisions. It is not binding on the US courts. This Guidance sets out a two-part test, with the second part itself divided into two steps. In step 1, the examiner must first decide if the claim is related broadly to patentable subject matter: is the claimed invention a process, machine or a composition of matter? If not, then the claim is not eligible subject matter. If it is, then the claim is analysed to determine if it relates in whole or in part to a judicial exception to patent-eligibility (step 2A). If not, then the claim satisfies the requirements of patent eligibility under Section 101. If the claim is determined to relate in part to a judicial exception, then the claim is analysed to determine if it recites additional elements that amount to significantly more than the judicial exception (step 2B). The analysis will only proceed to step 2B when the claim is directed to an exception, i.e. when no markedly different characteristics are shown.

We now consider how these steps are applied by the examiners through the use of illustrative examples that the USPTO has provided to its own examiners to assist them in guiding how they interpret the Interim Guidance of December 2014. We will then consider the practical implications for users of the patent system in the US seeking to obtain protections in the pharmaceutical and biotech fields.

Step 2A appears to be an important improvement for pharmaceutical and biotechnology companies in the approach to be adopted by examiners when considering eligibility of natural products when compared to the March 2014 Guidance. Thus, for example, under the December 2014 Guidance a combination product as a whole must be assessed to determine if it is markedly different from a product of nature. Under the March 2014 Guidance, evaluation of a combination of natural products was performed by individually comparing each component part to its naturally occurring form, and the effect of the combination of the products on, for example, the whole was not given.

As an example, under the March 2014 Guidance gunpowder was considered to be a combination of three naturally occurring products (potassium nitrate, charcoal and sulfur). Each was considered to be in its 'naturally occurring, unchanged state' in the mixture and it was not considered to display any of the exceptions set out in the final step of the March 2014 Guidance (equivalent to step 2B of the December 2014 Guidance). In the example published with the December 2014 Guidance, the analysis of gunpowder as a combination holds it to be markedly different from its naturally-occurring components because gunpowder is explosive, while the naturally-occurring substances on their own are not. This functional difference in the combination compared to the activities of the individual components enables subject matter eligibility to be acknowledged.

Another example where there has been a change in approach to combinations is seen in the example of a claim to a "beverage composition comprising pomelo juice and an effective amount of an added preservative". There is no naturally occurring counterpart to the claimed combination, so the combination is compared to the individual components as they occur in nature (Step 1: YES). Because of its "slower spoiling," the properties of the claimed combination are considered markedly different from the properties of the juice by itself in nature. (Step 2: NO). This is true regardless of whether the preservative is a natural product or a non-natural product. In the examples under the March 2014 Guidance, the composition comprising pomelo juice and another natural product (vitamin E) was considered patent ineligible as both were considered to be naturally occurring products which were unchanged in the combination, emphasising the importance of this change in approach resulting from considering the claim as a whole to determine if it is markedly different from a product of nature.

Another improvement in Step 2A is how Examiners should approach claims directed to or comprising isolated or purified natural products. Under the new Interim Guidance, such a product may be eligible if there is a resultant change in characteristics sufficient to show a marked difference from the natural counterpart. Differences that are exemplified include a change in the biological or pharmacological functions or activities, chemical or physical properties, changes in phenotype, or changes in structure and form, whether chemical, genetic or physical. Purified products were considered ineligible under the March 2014 Guidelines.

One example given together with the December 2015 Guidance is directed to a method claim reciting "a method of treating breast or colon cancer, comprising administering an effective amount of purified amazonic acid to a patient suffering from breast or colon cancer" is patent eligible under the new guidelines. The claim does not even require an analysis of "markedly different" because the claim is focused on a process of practically applying the product to treat a particular disease. Under the previous guidelines, such a claim was typically rejected as patent ineligible unless it also recited a dosage and/or a time period of administration. However it is to be noted that the analysis still considers that isolated purified amazonic acid is not patent eligible, despite the fact that the details of the example state that micrograms of the isolated compound are effective whereas a patient would have to ingest several tonnes of leaves to achieve the same effect, this is still considered to lack subject matter eligibility as the analysis argues that it is not 'markedly different' from the 'naturally occurring product in its natural state'.

For a claim that does not recite something "markedly different" from the natural counterpart (Step 2B), the Interim Guidance does not depart significantly from the March 2014 Guidance. The claim must be analysed to determine if elements other than those related to a judicial exception amount to something significantly more than the exception itself. The Interim Guidance provides examples of what is and is not considered "significantly more".

This is further emphasised by the example of 'purified Antibiotic L'. Under the Interim Guidance, a claim to this is deemed patent eligible. The different result is rationalised on the grounds that in the specification's definition of purified Antibiotic L, the claim is limited to Antibiotic L in the form of tetrahedral crystals or having a high-mannose N-glycan on residue 49. Thus, the claim does not encompass naturally occurring Antibiotic L (which forms hexagonal-pyramidal crystals, and has a bacillosamine N-glycan on residue 49).

An example of genetically modified bacterium illustrates that a naturally occurring product that is unchanged from its natural state ('A stable energy-generating plasmid, which provides a hydrocarbon degradative pathway) does not have markedly different characteristics and hence is not patent eligible: there is no information to suggest that they are markedly different from naturally-occurring energy-generating plasmids. However, a claim that incorporates changes in biological function between the claimed product and its natural counterpart ('A bacterium from the genus Pseudomonas containing therein at least two stable energy-generating plasmids, each of said plasmids providing a separate hydrocarbon degradative pathway') can demonstrate markedly different characteristics and hence be patent eligible: the bacterium comprising at least two plasmids is able to provide at least two hydrocarbon degradative pathways, compared to the naturally occurring counterpart that only has one, and hence is markedly different.

The public was invited by the USPTO to submit written comments up to 90 days from publication of the Interim Guidance in the Federal Register (a deadline of around 16 March 2015). This resulted in the issuance of further Guidance in July 2015. However, this did not address any issues relating to natural phenomena at all and was restricted to clarification of the guidance for abstract ideas.

The first months immediately after the issuance of the March 2014 Guidance saw a sharp rise in eligibility objections. Since the issuance of the December 2014 Guidelines, while the number of eligibility objections is still considerably higher than it was prior to the introduction of either sets of guidelines following Myriad and Mayo the impression of practitioners is that the number of eligibility objections has fallen. After all the clamour and the resultant partial retreat by the USPTO in the revised Interim Guidance, it is to be hoped that the promised 'balanced' approach is indeed starting to be seen in practice.

Time, of course, will tell and in the meantime we will be watching closely to determine how things develop and then devising the best strategies to adopt in this fast changing environment. However, we certainly advise at this stage that new applications in the US should include broader claims than might have been feared were allowable only a few months ago. It will be important, nevertheless, to ensure that fallback positions are included with specific limitations that may assist in overcoming any objections of lack of eligibility, e.g. specific crystal structures that are not found in nature, methods of treatment comprising specific dosage regimes, humanized antibodies and non-naturally occurring DNA sequences.

This article was originally published in MedNous.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.